ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1369

Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis

Amir Haddad1, Arane Thavaneswaran1, Dafna D. Gladman2 and Vinod Chandran3, 1Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with Psoriatic arthritis (PsA) who develop severe joint damage have severe functional disability and increased mortality risk. The most severe form of PsA is termed arthritis mutilans and is associated with severe erosions, osteolysis and pencil-in-cup change. Ankylosis is also a feature of severe PsA. The modified Steinbrocker method of scoring radiographic damage to peripheral joints in PsA recognizes grade 4 damage as severe damage, but does not explicitly distinguish between severe erosions, pencil-in-cup change, subluxation and ankylosis. We aimed to describe the prevalence and disease association of these features of severe joint damage in a cohort of patients with early PsA.

Methods: Patients presenting to a large PsA clinic with PsA duration of < 5years were identified. Patients are evaluated every 6-12 months and plain radiographs are obtained every 2 years. Radiographs are reviewed according to the modified Steinbrocker method by consensus of at least 2 rheumatologists. For this study radiographs that were scored as 4 were retrieved and rescored to indicate disorganization (4.0), subluxation (4.1), pencil-in-cup (4.2) and ankylosis (4.0). Subsequently, the clinical characteristics at first visit of patients who developed at least 1 joint with severe joint damage were compared to those without such damage.

Results: 664 patients who were enrolled  within 5 years of diagnosis were the subjects of this study. 116/664 (17.5%) were observed to have at least one joint with 4.0, 4.1, 4.2 or 4.3 of the 42 scored. The demographic and disease characteristics at first visit of the patients who were observed to develop such damage compared to those who did not are reported in table 1. Patients with severe joint damage were older at diagnosis of psoriasis and had longer PsA duration, but shorter psoriasis duration. They had higher active and damaged joint counts and ESR. There was a trend towards higher prevalence of female sex, axial disease and HLA-B*27 in those with severe damage. Of the 116 patients observed to develop severe damage, 34 (29%), 63 (54%), 36 (31%),  58 (50%) patients were observed to have ‘4.0′, ‘4.1′, ‘4.2′ and ‘4.3′, respectively at baseline or during follow-up. The mean (sd) number of joints with ‘4.0′, ‘4.1′, ‘4.2′ and ‘4.3′, were 0.3 (0.7), 1.1 (2.1), 0.6 (2.0) and 0.7 (1.4), respectively.  Only 15 (13%) patients were observed to have ankylosis without lysis. These patients had lower modified Steinbrocker score [mean, (sd) 31 (18) vs. 53 (43)      p=0.001] compared to those with subluxation or pencil-in-cup change.

Conclusion: Patients with PsA who develop severe joint damage have higher disease activity at presentation. The most common form of severe joint damage observed is subluxation. Only 13% have exclusive ankylosis. Further phenotypic characteristic of radiographic damage in PsA will facilitate genetic and mechanistic studies.

 Table 1. Demographics and Disease Characteristics at baseline

 

Variable

Patients with severe joint damage

N=116

Patients without severe joint damage

N=548

p-value

Gender (Males)

58 (50.0%)

322 (58.8%)

0.08

Age

43.8 (13.9)

41.7(12.9)

0.11

Age at diagnosis of Psoriasis

33.9 (15.5)

29.0 (14.6)

0.002

Age at diagnosis of PsA

41.4 (14.1)

39.8 (13.0)

0.27

Duration of Psoriasis

9.9 (10.1)

12.7 (11.6)

0.02

Duration of PsA

2.3 (1.6)

1.9 (1.7)

0.02

ESR

30.2 (20.5)

20.9 (19.6)

<0.0001

PASI score

6.3 (9.1)

5.9 (8.4)

0.76

Active joint count

12.9 (10.5)

9.4 (8.7)

0.001

Swollen joint count

5.7 (5.7)

4.7 (5.1)

0.09

Damage joint count

5.8 (5.2)

3.1 (4.0)

0.0008

Axial disease

41 (35.3%)

148 (27.0%)

0.07

HLA B*27

21 (22.6%)

59 (14.0%)

0.06

Follow-up time (radiographic visits)

11.6 (9.3)

5.3 (7.4)

<0.0001


Disclosure:

A. Haddad,
None;

A. Thavaneswaran,
None;

D. D. Gladman,
None;

V. Chandran,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/severe-joint-damage-in-psoriatic-arthritis-mutilans-and-ankylosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology